about
Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitorCapns1, a new binding partner of RasGAP-SH3 domain in K-Ras(V12) oncogenic cells: modulation of cell survival and migrationThe synaptic acetylcholinesterase tetramer assembles around a polyproline II helixReduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxelMolecular and cellular analysis of Grb2 SH3 domain mutants: interaction with Sos and dynaminEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyTGF-β2 induces Grb2 to recruit PI3-K to TGF-RII that activates JNK/AP-1-signaling and augments invasiveness of Theileria-transformed macrophages.The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.Affinity chromatography for purification of the modular protein growth factor receptor-bound protein 2 and development of a screening test for growth factor receptor-bound protein 2 Src homology 3 domain inhibitor using peroxidase-linked ligand.Design of peptoid analogue dimers and measure of their affinity for Grb2 SH3 domains.SH2 and SH3 domains as targets for anti-proliferative agents.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Parallel solid-phase synthesis of a small library of linear and hydrocarbon-bridged analogues of VEGF(81-91): potential biological tools for studying the VEGF/VEGFR-1 interaction.De novo designed library of linear helical peptides: an exploratory tool in the discovery of protein-protein interaction modulators.Biophysical Studies of the Induced Dimerization of Human VEGF Receptor 1 Binding Domain by Divalent Metals Competing with VEGF-A.Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.Guttiferone A Aggregates Modulate Silent Information Regulator 1 (SIRT1) Activity.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.Design, synthesis, and biological evaluation of the first podophyllotoxin analogues as potential vascular-disrupting agents.Synthetic route to dinuclear platinum(II) complexes [{trans-PtCl(NH3)2}2(mu-L)]2+ (L = aliphatic or heterocyclic diamine) as potential antitumor agents, exploiting the mutual activation of hydroxido ligands and ammonium groups.Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors.Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.[Search for new anti-angiogenic agents with structural analogy with thalidomide].Development of binding assays for the SH2 domain of Grb7 and Grb2 using fluorescence polarization.Helical peptides from VEGF and Vammin hotspots for modulating the VEGF-VEGFR interaction.Cyclic peptides as VEGF receptor antagonist.Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.Identification of Peptidic Antagonists of Vascular Endothelial Growth Factor Receptor 1 by Scanning the Binding Epitopes of Its Ligands.VEGFR1 domain 2 covalent labeling with horseradish peroxidase: Development of a displacement assay on VEGF.A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists.Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.
P50
Q24292256-98A81D66-1BAC-4756-B1CA-0966BB25A6D2Q24309140-B552427F-0E47-4B08-846F-D2878E00B95DQ24311587-2B63CA5D-E3C3-460A-990B-3DDB3916DC6BQ24321087-5902053F-6862-4453-99F0-EC5B60331622Q24658331-E741226C-80CB-41F7-8C61-3174D71971AFQ27618970-D329EC9A-9875-4233-83A1-B93866E2290EQ28482219-A1F942AF-75DA-4BE1-952C-F470DA95A903Q30009080-B33DCE8F-5680-43AD-B1D9-47B228C7B3E7Q30157685-AFC7FED5-E534-4AA1-8353-749A6EB26D4DQ30159911-F72456A4-90C3-4A0F-8D83-4623E514F0FAQ30164037-AB4658F7-1672-4246-8097-B8CA6AACB5F1Q30167833-87A371AB-763C-4063-851A-0E99B286C082Q33418378-145C85CB-0C97-44D3-BFD9-AF1C53D9703BQ33829423-2F54CEDE-C93F-4A5F-A73B-7120E60770CEQ35145940-DFE54DE6-0A11-40CB-AF95-426C6EAADBD4Q36220022-547E0B79-5FC8-4EC2-9752-0E03A94BC255Q37687194-6EEF2534-8B0F-4545-9A55-867827643DCCQ38201503-8BA5B54B-0BCC-456D-9BCB-FB955AAA4F4CQ38323440-B33CF7B3-E3FE-41EA-B4A6-EEF16B1C29BFQ38773565-62EA2702-DEB1-4A65-AFC5-57AD036AB393Q38817554-42C315DA-07CB-4F66-B365-FDFF506AC315Q38936104-8BAA00DB-77C9-4D5C-96A5-FF211D73431CQ39631802-54B01B29-F3F7-41A2-B739-4F9E27891FCFQ39639346-F9F35FD4-5BE0-4A80-A829-7D62B9396AD4Q39935811-BAE6A8AB-A5C3-472E-B9BF-508F454CBC58Q40043607-1236720E-1067-4429-A94B-83033C2B8F73Q40075451-49B173B9-A210-40B3-B8D1-482CC2C3CA15Q40698804-34814B0D-B7BE-4EE2-B102-457B75FBEA29Q44511953-CA4BD738-8230-4713-A216-98532712829BQ46415456-B1179870-2984-43F0-BCD3-4719D1F878A2Q46793863-76C795F4-0BCD-4BF3-AABE-BAFA97132E8DQ46819215-DDA8C916-24AF-4E56-BB13-1585A9D4F304Q47925008-975C781D-E88C-4641-A96A-10BF1241558BQ47962254-98FBBCF4-415F-4942-A076-33D35DB155A5Q48160367-DFB06AEB-4DEC-4609-BC01-A85B8F358E2FQ50647064-6F7A9110-47A3-4060-A0D2-B6CF05A7C3B3Q50978877-9F2E44DC-0C62-4F65-9702-6C3D94B1F1F3Q51049052-4563B16C-93DB-42B3-9D37-24AD3E990256Q51233060-0F80D18F-E83C-4629-ABB0-00DBEDD876B7Q52646840-0366CA5E-CEE9-4489-8C88-D55E721C83AB
P50
description
chercheur
@fr
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michel Vidal
@ast
Michel Vidal
@en
Michel Vidal
@es
Michel Vidal
@fr
Michel Vidal
@nl
Michel Vidal
@sl
type
label
Michel Vidal
@ast
Michel Vidal
@en
Michel Vidal
@es
Michel Vidal
@fr
Michel Vidal
@nl
Michel Vidal
@sl
prefLabel
Michel Vidal
@ast
Michel Vidal
@en
Michel Vidal
@es
Michel Vidal
@fr
Michel Vidal
@nl
Michel Vidal
@sl
P106
P21
P31
P496
0000-0002-4858-1591